2 July 2020
Pfizer and BioNTech have reported positive preliminary results from the ongoing Phase I/II clinical trial of BNT162b1, a potential Covid-19 vaccine. The results showed that the vaccine candidate could be given at a dose that was well tolerated and produced dose dependent immunogenicity.
At a UK parliamentary hearing, a researcher from the University of Oxford has said that the University’s Covid-19 vaccine candidate showed ‘the right sort of immune response’ in clinical trials. The vaccine, which has been licensed to AstraZeneca, is currently in Phase III trials on 8,000 volunteers. P
Sorrento Therapeutics has selected T-VIVA-19 as its targeted protein vaccine against Covid-19, as a result of findings from its preclinical vaccination programme. T-VIVA-19 is a recombinant fusion protein consisting of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc), which triggered antibodies against the SARS-CoV-2 protein in mice.
China National Biotec Group (CNBG) has completed construction of a new plant in Wuhan for Covid-19 vaccines, reported Reuters. The new facility, which has annual capacity of more than 100 million doses, is said to double CNBG’s capacity to over 200 million doses per year.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData